332 related articles for article (PubMed ID: 33714420)
1. Balanced evaluation of preliminary data on a candidate COVID-19 hydroxychloroquine treatment.
Seligmann H
Int J Antimicrob Agents; 2021 Mar; 57(3):106292. PubMed ID: 33714420
[No Abstract] [Full Text] [Related]
2. Effect of hydroxychloroquine and azithromycin on the viral clearance of SARS-CoV-2: response to Hervé Seligmann.
Gautret P; Hoang VT; Colson P; Raoult D
Int J Antimicrob Agents; 2021 Mar; 57(3):106306. PubMed ID: 33596459
[No Abstract] [Full Text] [Related]
3. Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: authors' response.
Fiolet T; Guihur A; Rebeaud ME; Mulot M; Peiffer-Smadja N; Mahamat-Saleh Y
Clin Microbiol Infect; 2021 Jan; 27(1):138-140. PubMed ID: 33080383
[No Abstract] [Full Text] [Related]
4. Has the door closed on hydroxychloroquine for SARS-COV-2?
Paul M
Clin Microbiol Infect; 2021 Jan; 27(1):3-5. PubMed ID: 33096242
[No Abstract] [Full Text] [Related]
5. Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia.
Mori N; Katayama M; Nukaga S
J Microbiol Immunol Infect; 2021 Feb; 54(1):109-112. PubMed ID: 33054978
[TBL] [Abstract][Full Text] [Related]
6. Hydroxychloroquine (HCQ): real treatment or false hope?
El Bakkouri K
Int J Antimicrob Agents; 2021 Jan; 57(1):106170. PubMed ID: 33408023
[No Abstract] [Full Text] [Related]
7. Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.
Million M; Roussel Y; Gautret P; Raoult D
Int J Antimicrob Agents; 2021 Jan; 57(1):106240. PubMed ID: 33408019
[No Abstract] [Full Text] [Related]
8. Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19.
Gautret P; Lagier JC; Honoré S; Hoang VT; Raoult D
Int J Antimicrob Agents; 2021 Jan; 57(1):106242. PubMed ID: 33408033
[No Abstract] [Full Text] [Related]
9. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited.
Gautret P; Lagier JC; Honoré S; Hoang VT; Colson P; Raoult D
Int J Antimicrob Agents; 2021 Jan; 57(1):106243. PubMed ID: 33408014
[No Abstract] [Full Text] [Related]
10. Interpretation of SARS-CoV-2 PCR results for the diagnosis of COVID-19.
Colson P; La Scola B; Lagier JC; Gautret P; Raoult D
Int J Antimicrob Agents; 2021 Jan; 57(1):106238. PubMed ID: 33408030
[No Abstract] [Full Text] [Related]
11. COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients.
Stewart M; Rodriguez-Watson C; Albayrak A; Asubonteng J; Belli A; Brown T; Cho K; Das R; Eldridge E; Gatto N; Gelman A; Gerlovin H; Goldberg SL; Hansen E; Hirsch J; Ho YL; Ip A; Izano M; Jones J; Justice AC; Klesh R; Kuranz S; Lam C; Mao Q; Mataraso S; Mera R; Posner DC; Rassen JA; Siefkas A; Schrag A; Tourassi G; Weckstein A; Wolf F; Bhat A; Winckler S; Sigal EV; Allen J
PLoS One; 2021; 16(3):e0248128. PubMed ID: 33730088
[TBL] [Abstract][Full Text] [Related]
12. Uncertain effects of hydroxychloroquine and azithromycin on SARS-Cov-2 viral load.
Nguyen TV
Int J Antimicrob Agents; 2021 Jan; 57(1):106169. PubMed ID: 33408026
[No Abstract] [Full Text] [Related]
13. Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.
Goldman JD; Diaz G; Urba WJ
Int J Antimicrob Agents; 2021 Jan; 57(1):106174. PubMed ID: 33408020
[No Abstract] [Full Text] [Related]
14. Azithromycin, a questionable treatment for COVID-19.
Belfaqeeh O; Janapala RN; Patel J; Alhashmi A; Pourmand A
Int J Antimicrob Agents; 2021 Mar; 57(3):106280. PubMed ID: 33476733
[No Abstract] [Full Text] [Related]
15. Hydroxychloroquine + azithromycin treatment in elderly patients.
Gautret P; Ly TDA; Raoult D
Int J Antimicrob Agents; 2021 Apr; 57(4):106313. PubMed ID: 33716178
[No Abstract] [Full Text] [Related]
16. Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes.
Gautret P; Hoang VT; Lagier JC; Raoult D
Int J Antimicrob Agents; 2021 Jan; 57(1):106239. PubMed ID: 33408029
[No Abstract] [Full Text] [Related]
17. Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".
Saad MO
Int J Antimicrob Agents; 2021 Jan; 57(1):106171. PubMed ID: 33408024
[No Abstract] [Full Text] [Related]
18. Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial.
Dos Santos MR
Int J Antimicrob Agents; 2021 Jan; 57(1):106176. PubMed ID: 33408022
[No Abstract] [Full Text] [Related]
19. Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity.
Hache G; Rolain JM; Gautret P; Deharo JC; Brouqui P; Raoult D; Honoré S
Microb Drug Resist; 2021 Mar; 27(3):281-290. PubMed ID: 33729874
[TBL] [Abstract][Full Text] [Related]
20. Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".
Wambier CG
Int J Antimicrob Agents; 2021 Jan; 57(1):106175. PubMed ID: 33408021
[No Abstract] [Full Text] [Related]
[Next] [New Search]
